KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $24.6 million.

  • Ionis Pharmaceuticals' Receivables - Other rose 3726.02% to $24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 3726.02%. This contributed to the annual value of $92.2 million for FY2024, which is 571.7% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Receivables - Other of $24.6 million as of Q3 2025, which was up 3726.02% from $52.6 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Receivables - Other peaked at $142.4 million during Q3 2023, and registered a low of $5.1 million during Q1 2024.
  • Moreover, its 5-year median value for Receivables - Other was $25.5 million (2022), whereas its average is $38.1 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Receivables - Other skyrocketed by 204234.76% in 2023 and then tumbled by 8740.65% in 2024.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Receivables - Other stood at $61.9 million in 2021, then crashed by 58.74% to $25.5 million in 2022, then surged by 282.87% to $97.8 million in 2023, then dropped by 5.72% to $92.2 million in 2024, then plummeted by 73.31% to $24.6 million in 2025.
  • Its last three reported values are $24.6 million in Q3 2025, $52.6 million for Q2 2025, and $39.7 million during Q1 2025.